BCM
ACRS icon

BlueCrest Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

BlueCrest Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,861
Closed -$255K – 801
2017
Q3 		$255K Buy
+9,861
New +$264K 0.01% 678

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BlueCrest Capital Management's ACRS Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 9,861 shares — an estimated $255K sold.

BlueCrest Capital Management first reported a position in ACRS in Q3 2017 and held it in 1 quarter. The position peaked at $255K in Q3 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 9,861 Aclaris Therapeutics shares in Q4 2017, an estimated $255K.
  • BlueCrest Capital Management first reported a position in Aclaris Therapeutics in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Aclaris Therapeutics position peaked at $255K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.